Treatment Patterns and Healthcare Resource Utilization in Pediatric NF1–Associated Symptomatic PN in the United States from 2000 to 2019
Clicks: 3
ID: 317407
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #22 of 42 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Neurofibromatosis type 1 (NF1) is a genetic condition that affects an estimated 1 in 3,000 people worldwide. NF1 is characterized by cutaneous hyperpigmented lesions and nerve-related neoplasia. To identify the unmet needs and understand the potential value of new treatments, the treatment patterns, healthcare resource utilization (HCRU), and clinical outcomes were evaluated in a real-world cohort of 102 pediatric patients with NF1 and plexiform neurofibroma (PN). Methods Retrospective data were collected from patients diagnosed with NF1 and symptomatic, inoperable PNs from 2000 to 2018 across 3 US sites. Data on clinical characteristics, site visits, treatments, and outcomes were collected through 2019. Results Patients with NF1, on average, developed 3.5 symptomatic, inoperable PNs during the study. PN complications included pain (76.5%), disfigurement (45.1%), and motor dysfunction (13.7%). During the study period, which was prior to FDA approval of MEK inhibitors for NF1, available treatments attempted to address the symptoms caused by PNs but did not typically slow or prevent their growth. Surgery was performed for 38.1% of study patients. At follow-up of ≥ 12 months, 62.5% of PNs regrew after surgery. Each year patients made, on average, 6 visits to an outpatient care center and 1 visit to an oncologist. Nearly all patients (99.0%) received at least 1 diagnostic imaging scan, with 3.4 scans per year on average. Conclusions This study describes the high burden of HCRU among pediatric patients with NF1-PN prior to FDA approval of pharmacologic therapies for PN and demonstrates the need for effective treatment options.
| Reference Key |
openalex_W7164822911
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Surya P. Rednam, Theresa Dettling, Michael Blackowicz, Randolph de la Rosa Rodríguez, Xiaoqin Yang, Saima Ali, Julia Meade |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag038
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.